查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423622

到 2030 年流感診斷市場預測：按產品類型、最終用戶和地區分類的全球分析

Influenza Diagnostics Market Forecasts to 2030 - Global Analysis By Product, Test Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球流感診斷市場規模將達到 23.2 億美元，預計 2030 年將達到 40.6 億美元，預測期內複合年成長率為 8.3%。

流感診斷包括識別和確認流感病毒感染的方法。抗原檢測等快速檢測透過檢測呼吸道檢體中的病毒蛋白來提供快速結果。聚合酶鏈反應 (PCR) 等分子測試透過檢測病毒的遺傳物質提供高靈敏度和特異性。這些方法可以幫助早期診斷並指導適當的治療和公共衛生干預措施。及時、準確的流感診斷有助於有效的病例管理、疫情控制和疫苗開發。

根據世界衛生組織（WHO）報告，到2023年，每年季節性流感患者人數將達到約10億人，其中3至500萬人病情嚴重。此外，流感每年導致全球 29 萬至 65 萬例呼吸道疾病死亡。

流感疫情增加

全球流感發病率的不斷上升強調了對高效、快速診斷工具的需求。市場對能夠快速準確檢測流感病毒的先進診斷技術的需求激增。這種不斷成長的需求正在推動創新診斷解決方案的研究和開發，並推動市場擴張。由於醫療保健系統優先考慮流感的早期檢測和有效管理，在全球減輕流感流行影響的迫切需求的推動下，流感診斷市場有望持續成長。

敏感性和特異性有限

流感診斷在檢測流感病毒方面發揮重要作用，但識別亞型和病毒株的準確性仍然令人擔憂。快速進化和抗原變異使診斷設計變得複雜，難以產生假陰性或區分流感亞型。假陽性和假陰性可能導致誤診，影響患者治療和公共衛生工作。平衡流感診斷的敏感性和特異性之間的權衡仍然是一個複雜的挑戰，阻礙了市場的成長。

活性化研究和開發

診斷技術（包括分子和快速檢測方法）的不斷進步正在提高流感檢測的準確性和效率。主要市場參與企業增加的研發投資和政府措施正在推動創新，從而開發出更可靠、更快速的診斷工具。研發活動的活性化不僅促進了技術突破，也為新的診斷解決方案鋪平了道路，最終推動市場成長。此外，該領域研究的動態格局被定位為市場擴張的關鍵驅動力。

與抗病毒藥物的競爭

隨著製藥業的不斷進步，抗病毒藥物將成為流感的主要治療方法，從而可能減少對診斷工具的需求。有效抗病毒治療的可用性可以降低快速且準確診斷解決方案的緊迫性，從而影響市場成長。競爭形勢向以治療為中心的方法的轉變凸顯了隨著流感管理動態的發展不斷創新以保持診斷的相關性和競爭力的必要性。

COVID-19 的影響

COVID-19 大流行對流感診斷市場產生了重大影響。人們對呼吸道感染疾病的認知不斷提高，由於與新冠病毒症狀重疊而對診斷測試的需求不斷增加，以及醫療基礎設施的激增正在對市場產生積極影響。此外，透過專注於先進的診斷技術和病毒學研究，流感診斷的創新正在不斷推進。然而，大流行期間供應鏈和醫療服務的中斷帶來了挑戰。整體來看，市場正經歷動態變化，疫情影響下機會與挑戰並存。

預計預測期內血清學檢測領域規模最大

血清學檢測領域預計將出現良好成長。血清學檢測透過檢測患者血清中的抗體來幫助識別和監測流感感染，在流感診斷中發揮重要作用。這種方法有助於區分當前和過去的感染，並可以全面了解個體的免疫反應。總體而言，血清學檢測的多功能性提高了診斷準確性，為預防策略提供資訊，並增強了流感感染的整體管理。

在預測期內，複合年成長率最高的將是臨床實驗室領域。

預計臨床實驗室產業在預測期內將經歷最高的複合年成長率。在臨床實驗室中，流感診斷在患者治療和公共衛生中發揮著至關重要的作用。快速且準確地識別流感病毒可以及時做出治療決定，並減少疾病的嚴重程度和持續時間。 PCR 檢測和快速抗原檢測等診斷檢測可實現早期檢測，並幫助醫護人員實施感染控制措施以防止進一步感染。這些測試將改善患者的治療結果，支持公共衛生舉措，為疫苗接種策略提供訊息，並確保臨床實驗室在有效的流感管理和控制中發揮重要作用。

比最大的地區

由於意識的提高、醫療保健支出的增加以及流感病例的激增，亞太地區預計將在預測期內佔據最大的市場佔有率。在該地區，PCR檢測和快速流感檢測等先進診斷技術備受關注。此外，政府舉措加上對現場檢測需求的不斷成長正在推動市場擴張。羅氏診斷公司 (Roche Diagnostics)、雅培實驗室 (Abbott Laboratories) 和賽默飛世爾科技 (Thermo Fisher Scientific) 等主要企業正致力於策略聯盟和產品創新，以提高其市場佔有率。在積極的公共衛生舉措和診斷技術不斷進步的推動下，亞太地區流感診斷市場預計將持續成長。

複合年成長率最高的地區：

由於流感流行不斷增加以及對準確及時診斷解決方案的持續需求，預計北美在預測期內將呈現最高的複合年成長率。該地區對快速、靈敏的診斷工具的需求強勁，推動了技術進步。 Luminex Corporation、DiaSorin 和 Becton, Dickinson and Company (BD) 等主要企業專注於 PCR 和免疫測量等創新技術，以實現高效流感檢測。市場受到政府措施、意識不斷提高以及即時檢測需求等因素的影響。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球流感診斷市場：按產品

  • 裝置
  • 套件和試劑
  • 其他產品

第6章全球流感診斷市場：依測試類型

  • 傳統診斷測試
    • 病毒培養
    • 直接螢光抗體測試 (DFAT)
    • 流感快速診斷檢驗 (RIDT)
  • 分子診斷分析
    • 基於簡單擴增的測定 (SAMBA)
    • 基於核酸序列的擴增檢驗 (NASBAT)
    • 基於恒溫環型核酸擴增的測定（LAMP）
    • 逆轉錄聚合酶連鎖反應 (RT-PCR)
  • 血清學檢測
    • 血凝抑制 (HI) 測定
    • 微量中和測定
  • 其他測試類型

第7章全球流感診斷市場：依最終使用者分類

  • 即時檢測
  • 醫院
  • 臨床實驗室
  • 學術/研究機構
  • 居家照護環境
  • 其他最終用戶

第8章全球流感診斷市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Altona Diagnostics GmbH
  • ELITech Group
  • GenMark Diagnostics
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Becton, Dickinson, and Company
  • Coris BioConcept
  • DiaSorin SpA
  • Meridian Bioscience Inc.
  • Quidel Corporation
  • Sekisui Diagnostics
  • Thermo Fischer Scientific Inc.
  • Hologic Inc.
  • Mast Group
  • Siemens Healthineers AG
  • BioMerieux SA
  • Luminex Corporation
Product Code: SMRC24856

According to Stratistics MRC, the Global Influenza Diagnostics Market is accounted for $2.32 billion in 2023 and is expected to reach $4.06 billion by 2030 growing at a CAGR of 8.3% during the forecast period. Influenza diagnostics involve methods to identify and confirm influenza virus infections. Rapid tests, such as antigen detection assays, provide quick results by detecting viral proteins in respiratory samples. Molecular tests, like polymerase chain reaction (PCR), offer high sensitivity and specificity by detecting viral genetic material. These methods aid in early diagnosis, guiding appropriate treatment and public health interventions. Timely and accurate influenza diagnostics enables effective patient management, outbreak control and vaccine development.

According to the World Health Organization report, in 2023, there were around a billion cases of seasonal influenza annually, including 3-5 million cases of severe illness. Moreover, influenza causes 290,000 to 650,000 respiratory deaths annually around the globe.

Market Dynamics:

Driver:

Rising prevalence of influenza

The increasing incidence of influenza cases worldwide underscores the critical need for efficient and rapid diagnostic tools. The market is witnessing a surge in demand for advanced diagnostic technologies capable of swift and accurate detection of influenza viruses. This heightened demand is steering research and development efforts towards innovative diagnostic solutions, fostering market expansion. As healthcare systems prioritize early detection and effective management of influenza, the influenza diagnostics market is poised to witness sustained growth, driven by the urgent global health imperative to mitigate the impact of influenza outbreaks.

Restraint:

Limited sensitivity & specificity

While influenza diagnostics play a crucial role in detecting influenza viruses, their accuracy in differentiating between subtypes and strains remains a concern. Rapid evolution and antigenic variability challenge the design of diagnostics, leading to false negatives or difficulty in distinguishing between influenza subtypes. False positives and negatives can lead to misdiagnoses, impacting patient care and public health efforts. Balancing the trade-off between sensitivity and specificity remains a complex task in influenza diagnostics, which hinder the market growth.

Opportunity:

Growing research & development activities

Ongoing advancements in diagnostic technologies, such as molecular and rapid testing methods, are enhancing the accuracy and efficiency of influenza detection. Increasing investments in R&D by key market players and government initiatives are driving innovation, leading to the development of more reliable and rapid diagnostic tools. This surge in R&D activities not only fosters technological breakthroughs but also opens avenues for novel diagnostic solutions, ultimately propelling the growth of the market. Also, the dynamic landscape of research in this field positions it as a crucial driver for market expansion.

Threat:

Competition from antiviral medications

As pharmaceutical advancements continue, antiviral drugs gain prominence as a primary intervention for influenza, potentially diminishing the demand for diagnostic tools. The availability of effective antiviral treatments may reduce the urgency for rapid and accurate diagnostic solutions, impacting the market's growth. The healthcare landscape's shift towards treatment-oriented approaches underscores the need for constant innovation in diagnostics to maintain relevance and competitiveness amid the evolving dynamics of influenza management.

Covid-19 Impact

The covid-19 pandemic has significantly influenced the influenza diagnostics market. Increased awareness of respiratory infections, heightened demand for diagnostic testing due to overlapping symptoms with covid, and a surge in healthcare infrastructure have positively impacted the market. Additionally, the focus on advanced diagnostic technologies and research in virology has driven innovation in influenza diagnostics. However, disruptions in the supply chain and healthcare services during the pandemic have presented challenges. Overall, the market has experienced a dynamic shift with both opportunities and obstacles arising from the epidemic impact.

The serological testing segment is expected to be the largest during the forecast period

The serological testing segment is estimated to have a lucrative growth. Serological testing plays a crucial role in Influenza Diagnostics by detecting antibodies in a patient's blood serum, aiding in the identification and monitoring of influenza infections. This method helps differentiate between current and past infections, allowing for a comprehensive understanding of an individual's immune response. Overall, the versatility of serological testing enhances diagnostic accuracy, informs preventative strategies, and strengthens the overall management of influenza infections.

The clinical laboratories segment is expected to have the highest CAGR during the forecast period

The clinical laboratories segment is anticipated to witness the highest CAGR growth during the forecast period. In clinical laboratories, influenza diagnostics play a pivotal role in patient care and public health. Rapid and accurate identification of influenza viruses aids in timely treatment decisions, reducing the severity and duration of illness. Diagnostic tests, including PCR and rapid antigen assays, enable early detection, helping healthcare professionals implement infection control measures to prevent further transmission. These tests enhance patient outcomes, support public health initiatives, and inform vaccination strategies, demonstrating their indispensable role in clinical laboratories for effective influenza management and control.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increased awareness, rising healthcare expenditure, and a surge in influenza cases. Advanced diagnostic technologies, such as PCR and rapid influenza detection tests, are gaining prominence in the region. Additionally, government initiatives coupled with the growing demand for point-of-care testing, are driving market expansion. Key players such as Roche Diagnostics, Abbott Laboratories and Thermo Fisher Scientific are focusing on strategic collaborations and product innovations to strengthen their market presence. The Asia Pacific Influenza Diagnostics Market is poised for continued growth, driven by a proactive approach to public health and the continual evolution of diagnostic technologies.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increasing prevalence of influenza and the constant need for accurate and timely diagnostic solutions. The region witnesses a robust demand for rapid and sensitive diagnostic tools, driving technological advancements. Key players in the market like Luminex Corporation, DiaSorin and Becton, Dickinson and Company (BD) focus on innovative techniques like PCR and immunoassays for efficient influenza detection. The market is influenced by factors such as government initiatives, rising awareness, and the need for point-of-care testing.

Key players in the market

Some of the key players profiled in the Influenza Diagnostics Market include Altona Diagnostics GmbH, ELITech Group, GenMark Diagnostics, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Becton, Dickinson, and Company, Coris BioConcept, DiaSorin SpA, Meridian Bioscience Inc., Quidel Corporation, Sekisui Diagnostics, Thermo Fischer Scientific Inc., Hologic Inc., Mast Group, Siemens Healthineers AG, BioMerieux SA and Luminex Corporation.

Key Developments:

In September 2022, Siemens Healthineers released its new CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test. Validated on the company's VERSANT kPCR Molecular System, the kit combines Siemens Healthineers FTD SARS-CoV-23 and FTD Flu/HRSV Assays.

In February 2022, Roche announced the expansion of the COVID-19 PCR portfolio to the cobas® 5800 System, a recently launched molecular laboratory instrument, in countries accepting the CE mark. These include cobas SARS-CoV-2 Qualitative and cobas SARS-CoV-2 & Influenza A/B tests. These launches expand the Roche Diagnostics molecular portfolio offering by providing standardized performance and efficiencies across low, medium and high volume molecular laboratory testing needs.

Products Covered:

  • Instruments
  • Kits & Reagents
  • Other Products

Test Types Covered:

  • Traditional Diagnostic Test
  • Molecular Diagnostic Assay
  • Serological Testing
  • Other Test Types

End Users Covered:

  • Point-of-Care Testing
  • Hospitals
  • Clinical Laboratories
  • Academic/Research Institutes
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Influenza Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Kits & Reagents
  • 5.4 Other Products

6 Global Influenza Diagnostics Market, By Test Type

  • 6.1 Introduction
  • 6.2 Traditional Diagnostic Test
    • 6.2.1 Viral Culture
    • 6.2.2 Direct Fluorescent Antibody Test (DFAT)
    • 6.2.3 Rapid Influenza Diagnostic Test (RIDT)
  • 6.3 Molecular Diagnostic Assay
    • 6.3.1 Simple Amplification-based Assay (SAMBA)
    • 6.3.2 Nucleic Acid Sequence-based Amplification Test (NASBAT)
    • 6.3.3 Loop-mediated Isothermal Amplification-based Assay (LAMP)
    • 6.3.4 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
  • 6.4 Serological Testing
    • 6.4.1 Hemagglutination Inhibition (HI) Assays
    • 6.4.2 Microneutralization Assays
  • 6.5 Other Test Types

7 Global Influenza Diagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Point-of-Care Testing
  • 7.3 Hospitals
  • 7.4 Clinical Laboratories
  • 7.5 Academic/Research Institutes
  • 7.6 Homecare Settings
  • 7.7 Other End Users

8 Global Influenza Diagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Altona Diagnostics GmbH
  • 10.2 ELITech Group
  • 10.3 GenMark Diagnostics
  • 10.4 F. Hoffmann-La Roche Ltd
  • 10.5 Abbott Laboratories
  • 10.6 Becton, Dickinson, and Company
  • 10.7 Coris BioConcept
  • 10.8 DiaSorin SpA
  • 10.9 Meridian Bioscience Inc.
  • 10.10 Quidel Corporation
  • 10.11 Sekisui Diagnostics
  • 10.12 Thermo Fischer Scientific Inc.
  • 10.13 Hologic Inc.
  • 10.14 Mast Group
  • 10.15 Siemens Healthineers AG
  • 10.16 BioMerieux SA
  • 10.17 Luminex Corporation

List of Tables

  • Table 1 Global Influenza Diagnostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Influenza Diagnostics Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Influenza Diagnostics Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 4 Global Influenza Diagnostics Market Outlook, By Kits & Reagents (2021-2030) ($MN)
  • Table 5 Global Influenza Diagnostics Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 6 Global Influenza Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 7 Global Influenza Diagnostics Market Outlook, By Traditional Diagnostic Test (2021-2030) ($MN)
  • Table 8 Global Influenza Diagnostics Market Outlook, By Viral Culture (2021-2030) ($MN)
  • Table 9 Global Influenza Diagnostics Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2021-2030) ($MN)
  • Table 10 Global Influenza Diagnostics Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2021-2030) ($MN)
  • Table 11 Global Influenza Diagnostics Market Outlook, By Molecular Diagnostic Assay (2021-2030) ($MN)
  • Table 12 Global Influenza Diagnostics Market Outlook, By Simple Amplification-based Assay (SAMBA) (2021-2030) ($MN)
  • Table 13 Global Influenza Diagnostics Market Outlook, By Nucleic Acid Sequence-based Amplification Test (NASBAT) (2021-2030) ($MN)
  • Table 14 Global Influenza Diagnostics Market Outlook, By Loop-mediated Isothermal Amplification-based Assay (LAMP) (2021-2030) ($MN)
  • Table 15 Global Influenza Diagnostics Market Outlook, By Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) (2021-2030) ($MN)
  • Table 16 Global Influenza Diagnostics Market Outlook, By Serological Testing (2021-2030) ($MN)
  • Table 17 Global Influenza Diagnostics Market Outlook, By Hemagglutination Inhibition (HI) Assays (2021-2030) ($MN)
  • Table 18 Global Influenza Diagnostics Market Outlook, By Microneutralization Assays (2021-2030) ($MN)
  • Table 19 Global Influenza Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 20 Global Influenza Diagnostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 21 Global Influenza Diagnostics Market Outlook, By Point-of-Care Testing (2021-2030) ($MN)
  • Table 22 Global Influenza Diagnostics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Influenza Diagnostics Market Outlook, By Clinical Laboratories (2021-2030) ($MN)
  • Table 24 Global Influenza Diagnostics Market Outlook, By Academic/Research Institutes (2021-2030) ($MN)
  • Table 25 Global Influenza Diagnostics Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 26 Global Influenza Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.